Yahoo Finance EN

BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush

Mar 10, 2026 &03021010202631; 12:02 UTC finance.yahoo.com Trending 3/5

Read original on finance.yahoo.com ↗

↗

Positive for markets

Sentiment score: +65/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Wedbush has raised its price target on BioCryst Pharmaceuticals (BCRX), signaling improved confidence in the company's prospects. This analyst upgrade typically reflects positive developments in the company's pipeline, financial performance, or market positioning.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

BCRX

BCRXStock

Expected to rise

Analyst price target raise by Wedbush indicates positive outlook on company fundamentals and growth prospects

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating BCRX on any pullbacks following this upgrade, as analyst price target raises often precede institutional buying. Monitor for additional analyst upgrades and clinical trial updates to confirm the bullish thesis.

KEY SIGNALS

Analyst upgradePrice target increaseImproved investor confidencePotential pipeline advancement

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 11, 2026 at 02:50 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush

RELATED INTELLIGENCE